Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .
Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT01738945
- Locations
- 🇹🇷
Gulhane School of Medicine, Ankara, Turkey
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 454
- Registration Number
- NCT01692301
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2012-08-15
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01665235
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
- Conditions
- Interventions
- First Posted Date
- 2012-08-13
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 266
- Registration Number
- NCT01663233
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 17
- Registration Number
- NCT01658657
- Locations
- 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT01631864
- Locations
- 🇳🇱
Novartis Investigative Site, Maastricht, Netherlands
Vascular Augmentation of Late-life Unremitted Depression (VALUeD)
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- Gateshead Health NHS Foundation Trust
- Target Recruit Count
- 80
- Registration Number
- NCT01557153
- Locations
- 🇬🇧
Clinical Ageing Research Unit, Newcastle upon Tyne, United Kingdom
Perindopril Amlodipine for the Treatment of Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Symplmed Pharmaceuticals LLC
- Target Recruit Count
- 837
- Registration Number
- NCT01556997
A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Ottawa Hospital Research Institute
- Registration Number
- NCT01549496
- Locations
- 🇨🇦
Clinical Investigation Unit, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 100
- Registration Number
- NCT01490255
- Locations
- 🇮🇹
San Raffaele Pisana, Rome, Italy
🇮🇹University La Sapienza, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.